Proteostasis Therapeutics, a clinical stage biopharmaceutical company developing small molecule therapeutics, completed the merger with Yumanity Therapeutics, a clinical-stage biopharmaceutical company, in an all-stock deal. Financial terms were not disclosed. “Our joining the NASDAQ stock exchange through this merger marks a transformative moment in the history of the company as we look to deliver disease-modifying treatments to patients suffering from neurodegenerative diseases. Our accelerating momentum will continue into 2021 as we look to deliver clinical data from our lead program for Parkinson’s disease as well as advance several other programs from our diverse portfolio of assets," Richard Peters, Yumanity President, Chief Executive Officer, and Director.